1 October 2008 - Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced that it had been granted a patent in the U.S. for methods to produce certain proteins in yeast. Among the proteins whose production is covered by the patent (United States Patent 7,419,801) is recombinant alpha 1-antitrypsin (rAAT), the protein used in Respriva™, the company’s lead product. “This patent extends our patent portfolio and strengthens our intellectual property estate for Respriva™,” said Sue Preston, chief executive officer of Arriva. “As we move forward with the development of Respriva™, we have multiple competitive advantages that leave us well positioned in the global market.”
Respriva™ is an inhaled rAAT. Arriva is currently conducting clinical trials with Respriva™ as replacement therapy in hereditary emphysema (HE). Patients with HE have a congenital deficiency in naturally occurring alpha 1-antitrypsin (AAT). Respriva™ also has the potential to ameliorate lung disease in other indications, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis... [PDF] Arriva Pharmaceuticals' Press Release -
